RxDoctor Payments Data

Rachel Ford

Women's Health · Jackson, MSNPI 1346652377

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 48.2% of the total.

$2,582in general payments, 2019–2025

Across 150 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$262
  • Pfizer$215
  • Lilly USA, LLC$178
  • GSK$64
  • Boehringer Ingelheim$62
  • plus $556 from 21 others

What the payments were for

  • Food & beverage$2,52998%
  • Other$532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,582 in reported general payments places this provider in the 85th percentile of 66 women's health providers in Mississippi.

See all women's health providers in Mississippi

Medicare billing

Part B allowed, 2024
$127,671
Medicare patients
456
Services billed
4,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$14,302
QuliptaAtogepant11$7,450
MyrbetriqMirabegron14$7,047
Doxycycline Hyclate125$1,312
Albuterol Sulfate HfaAlbuterol Sulfate25$1,087
SynthroidLevothyroxine Sodium14$1,003
Cefdinir49$875
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst38$798
CefuroximeCefuroxime Axetil33$696
Levothyroxine Sodium80$558
Rosuvastatin Calcium61$494
Gabapentin46$444
Metformin Hcl62$366
Metoprolol Succinate32$357
Ciprofloxacin Hcl56$340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$14,30215 claims
AbbVieQulipta, Synthroid$1,245$8,45325 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$55880 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 66 women's health providers in Mississippi.

Other women's health in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →